These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9393292)

  • 21. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
    van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
    Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a quality-of-life scale for Chinese patients with benign prostatic hyperplasia.
    Shi J; Sun Z; Cai T; Yang L
    BJU Int; 2004 Oct; 94(6):837-44. PubMed ID: 15476519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.
    Hansen BJ; Mortensen S; Mensink HJ; Flyger H; Riehmann M; Hendolin N; Nordling J; Hald T
    Br J Urol; 1998 Jan; 81(1):36-41. PubMed ID: 9467474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
    Sánchez-Chapado M; Guil M; Alfaro V; Badiella L; Fernández-Hernando N
    Eur Urol; 2000 Apr; 37(4):421-7. PubMed ID: 10765072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
    Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
    Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of benign prostatic hyperplasia on general well-being of men.
    Tsang KK; Garraway WM
    Prostate; 1993; 23(1):1-7. PubMed ID: 7687780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
    Buzelin JM; Hebert M; Blondin P
    Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Benign prostatic hyperplasia and its treatment: impact on quality of life and sexual function].
    Castro-Díaz D; Díaz-Cuervo H; Pérez M
    Actas Urol Esp; 2013 Apr; 37(4):233-41. PubMed ID: 23246106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development and validation of a quality of life scale associated with health status, specific for benign hypertrophy of the prostate and including a sexuality evaluation scale].
    Lukacs B; McCarthy C; Leplege A; Comet D
    Prog Urol; 1994 Oct; 4(5):688-99. PubMed ID: 7532071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study.
    Calais Da Silva F; Marquis P; Deschaseaux P; Gineste JL; Cauquil J; Patrick DL
    Eur Urol; 1997; 31(3):272-80. PubMed ID: 9129915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scoring the short form ICSmaleSF questionnaire. International Continence Society.
    Donovan JL; Peters TJ; Abrams P; Brookes ST; de aa Rosette JJ; Schäfer W
    J Urol; 2000 Dec; 164(6):1948-55. PubMed ID: 11061889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.
    Barry MJ; Fowler FJ; O'Leary MP; Bruskewitz RC; Holtgrewe HL; Mebust WK
    Med Care; 1995 Apr; 33(4 Suppl):AS145-55. PubMed ID: 7536866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
    Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
    Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.